JP5547096B2 - 多型を最小化する方法 - Google Patents
多型を最小化する方法 Download PDFInfo
- Publication number
- JP5547096B2 JP5547096B2 JP2010548864A JP2010548864A JP5547096B2 JP 5547096 B2 JP5547096 B2 JP 5547096B2 JP 2010548864 A JP2010548864 A JP 2010548864A JP 2010548864 A JP2010548864 A JP 2010548864A JP 5547096 B2 JP5547096 B2 JP 5547096B2
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- dosage form
- gelatin
- pharmaceutically active
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(a) 担体物質における連続相において粒子の懸濁物を形成する工程であって、担体物質がさらに標準分子量魚ゼラチンを含む、工程;
(b) 懸濁温度を約15°Cより低い温度に低下させる工程;
(c) 懸濁温度を約15°Cより低い温度に維持する工程;
(d) 約15°Cより低い形成温度で、不連続単位の懸濁物を形成する工程;
(e) 連続相を除去し、担体物質中に粒子の懸濁物を残す工程。
を含む薬学的活性物質の経口固体FDDFを調製する方法が開示される。
(a) 担体物質における連続相において、水性環境にさらされる場合、結晶変換に感受性である薬剤を含む、薬剤のクラスから選択される少なくとも一種の粒子の懸濁物を形成する工程であって、担体物質がさらに標準分子量魚ゼラチンを含む、工程;
(b) 懸濁温度を約15°Cより低い温度に低下させる工程;
(c) 懸濁温度を約15°Cより低い温度に維持する工程;
(d) 約15°Cより低い形成温度で、不連続単位の懸濁物を形成する工程;ならびに
(e) 連続相を除去し、担体物質中に粒子の懸濁物を残す工程。
を含む薬学的活性物質の経口固体FDDFを調製する方法も開示される。
Claims (14)
- ベンゾジアゼピンである薬学的活性物質の経口固体急速分散性投与剤形を調製する方法であって、
(a)連続相に存在する担体物質中で、前記薬学的活性物質の粒子の懸濁物を形成させる工程であって、担体物質が分子量分散の少なくとも50重量%が30,000ダルトン未満である魚ゼラチンを含む、工程;
(b)前記懸濁物の懸濁温度を15°Cより低い温度に低下させる工程;
(c)15°Cより低い形成温度で、前記懸濁物の不連続単位を形成させる工程;および
(d)連続相を除去し、担体物質中に粒子の懸濁物を残留させる工程
を含み、前記薬学的活性物質が水性環境において結晶多型を示す、方法。 - 連続相が水を含む、請求項1に記載の方法。
- 薬学的活性物質がアルプラゾラムである、請求項1に記載の方法。
- 急速分散性投与剤形が、1秒から60秒の崩壊時間を有する、請求項1に記載の方法。
- 前記懸濁物が、着色剤、芳香剤、賦形剤、他の医薬およびそれらの組み合わせからなる群より選択される少なくとも一つの付加成分を含む、請求項1に記載の方法。
- 請求項1に記載の方法により調製される、前記薬学的活性物質を含む急速分散性投与剤形。
- 中枢神経系疾患を治療するための、請求項6に記載の急速分散性投与剤形。
- 前記中枢神経系疾患が、不安疾患、症候性不全失語症、パニック疾患、けいれん疾患、統合失調症および二極性(躁鬱)疾患からなる群より選択される、請求項7に記載の急速分散性投与剤形。
- 薬学的活性物質の経口固体急速分散性投与剤形を調製する方法であって、
(a)連続相に存在する担体物質中で、ベンゾジアゼピンの粒子の懸濁物を形成させる工程であって、担体物質が分子量分散の少なくとも50重量%が30,000ダルトン未満である魚ゼラチンを含む、工程;
(b)15°Cより低い温度に懸濁温度を低下させ、懸濁物の温度を15°C未満に維持する工程;
(c)15°Cより低い形成温度で、懸濁物の不連続単位を形成させる工程;および
(d)連続相を除去し、担体物質中に粒子の懸濁物を残留させる工程
を含み、前記薬学的活性物質が水性環境において結晶多型を示す、方法。 - 請求項9に記載の方法により調製される急速分散性投与剤形。
- 懸濁物の粘度が、15°C以下の温度で少なくとも48時間の時間にわたって、もとの懸濁物の粘度から50%よりも低く変動する、請求項9に記載の方法により調製される急速分散性固体投与剤形。
- 連続相が水である、請求項11に記載の急速分散性固体投与剤形。
- 着色剤、芳香剤、賦形剤、他の医薬およびそれらの組み合わせからなる群より選択される少なくとも一つの付加成分をさらに含む、請求項11に記載の急速分散性固体投与剤形。
- 混合物からの溶媒の除去を、凍結乾燥により実行する、請求項12に記載の急速分散性固体投与剤形。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3229808P | 2008-02-28 | 2008-02-28 | |
US61/032,298 | 2008-02-28 | ||
PCT/US2009/035276 WO2009108775A2 (en) | 2008-02-28 | 2009-02-26 | Process to minimize polymorphism |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013256105A Division JP2014062119A (ja) | 2008-02-28 | 2013-12-11 | 多型を最小化する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011513324A JP2011513324A (ja) | 2011-04-28 |
JP5547096B2 true JP5547096B2 (ja) | 2014-07-09 |
Family
ID=41016708
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010548864A Active JP5547096B2 (ja) | 2008-02-28 | 2009-02-26 | 多型を最小化する方法 |
JP2013256105A Pending JP2014062119A (ja) | 2008-02-28 | 2013-12-11 | 多型を最小化する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013256105A Pending JP2014062119A (ja) | 2008-02-28 | 2013-12-11 | 多型を最小化する方法 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20090226522A1 (ja) |
EP (1) | EP2247284B1 (ja) |
JP (2) | JP5547096B2 (ja) |
KR (1) | KR101473419B1 (ja) |
CN (2) | CN103751091B (ja) |
AR (1) | AR072245A1 (ja) |
AU (1) | AU2009219292B2 (ja) |
BR (1) | BRPI0908539B8 (ja) |
CA (1) | CA2716901C (ja) |
DK (1) | DK2247284T3 (ja) |
ES (1) | ES2633928T3 (ja) |
HK (1) | HK1154505A1 (ja) |
IL (2) | IL207824A (ja) |
MX (1) | MX2010009493A (ja) |
MY (1) | MY173867A (ja) |
NZ (1) | NZ587611A (ja) |
RU (1) | RU2010139643A (ja) |
WO (1) | WO2009108775A2 (ja) |
ZA (1) | ZA201006421B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR083361A1 (es) * | 2010-10-08 | 2013-02-21 | Scherer Technologies Inc R P | Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon |
HUE055000T2 (hu) | 2015-02-27 | 2021-10-28 | Dechra Ltd | Étvágy stimulálása, tömegvesztés kézbentartása és anorexia kezelése kutyák és macskák esetében |
CN107951893B (zh) * | 2016-10-18 | 2022-04-26 | 天津金耀集团有限公司 | 一种糠酸莫米松粉吸入剂组合物 |
BR112019013503A2 (pt) | 2016-12-31 | 2020-01-07 | Bioxcel Therapeutics, Inc. | Uso de dexmedetomidina sublingual para o tratamento da agitação |
CN114983981A (zh) | 2018-06-27 | 2022-09-02 | 比奥克斯塞尔医疗股份有限公司 | 含右美托咪定的膜制剂及其制造方法 |
CN109010295A (zh) * | 2018-08-29 | 2018-12-18 | 北京兴源联合医药科技有限公司 | 一种左甲状腺素钠冻干口腔崩解片 |
CN109316452B (zh) * | 2018-09-07 | 2021-07-30 | 北京兴源联合医药科技有限公司 | 一种硫酸氢氯吡格雷冻干口腔崩解片 |
JP2022521317A (ja) | 2019-02-22 | 2022-04-06 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | 医薬品の崩壊時間を安定させるための、保管中の薬物粒子コーティング材料の凝集を最小限に抑える |
ES2966816T3 (es) | 2019-02-22 | 2024-04-24 | Catalent Uk Swindon Zydis Ltd | Minimización de la aglomeración, aireación y conservación del recubrimiento de composiciones farmacéuticas que comprenden ibuprofeno |
MX2022000709A (es) | 2019-07-19 | 2022-05-19 | Bioxcel Therapeutics Inc | Regimenes de tratamiento con dexmedetomidina no sedante. |
JP2023535829A (ja) * | 2020-07-31 | 2023-08-21 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | コーティングされたapiを含む医薬組成物 |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US4946684A (en) * | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
DD289468B5 (de) | 1989-11-07 | 1994-02-10 | Dresden Arzneimittel | Arzneimitteltechnologisches verfahren zur herstellung einer alprazolam-arzneiform |
CA2020018A1 (en) * | 1990-06-27 | 1991-12-28 | Don L. Simmons | Method and composition for treating the migraine complex |
JP3069458B2 (ja) * | 1992-01-29 | 2000-07-24 | 武田薬品工業株式会社 | 口腔内崩壊型錠剤およびその製造法 |
ATE208615T1 (de) * | 1993-07-09 | 2001-11-15 | Scherer Corp R P | Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen |
US5457895A (en) * | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
CZ289649B6 (cs) * | 1994-07-22 | 2002-03-13 | Krka, Tovarna Zdravil. P.O. | Pevné lékové formy se spolehlivým uvolňováním aktivní sloľky alprazolamu a způsob jejich přípravy |
ES2217410T3 (es) * | 1996-04-16 | 2004-11-01 | Novartis Consumer Health S.A. | Forma de dosificacion oral de rapida desintegracion. |
EP0839526A3 (en) * | 1996-10-31 | 1999-01-07 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with fast buccal disintegration or dissolution |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
US6010719A (en) * | 1997-09-16 | 2000-01-04 | Universiteit Gent | Freeze-dried disintegrating tablets |
KR100607008B1 (ko) | 1997-12-26 | 2006-08-01 | 워너-램버트 캄파니 엘엘씨 | 젤라틴 조성물 |
GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
US6509040B1 (en) * | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
CA2448864C (en) * | 2001-06-22 | 2008-04-22 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
US7972621B2 (en) * | 2004-06-03 | 2011-07-05 | R.P. Scherer Technologies, Llc | Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight |
US7855196B2 (en) * | 2005-08-22 | 2010-12-21 | Pierre Mainville | Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist |
BRPI0617693A2 (pt) * | 2005-11-09 | 2011-08-02 | Dow Pharmaceutical Sciences | azitromicina para o tratamento de rosácea granulomatosa |
GB0714223D0 (en) * | 2007-07-20 | 2007-08-29 | Fujifilm Mfg Europe Bv | Preparation of fine particles |
-
2009
- 2009-02-26 MX MX2010009493A patent/MX2010009493A/es active IP Right Grant
- 2009-02-26 NZ NZ587611A patent/NZ587611A/en unknown
- 2009-02-26 KR KR1020107021356A patent/KR101473419B1/ko active IP Right Grant
- 2009-02-26 MY MYPI2010004071A patent/MY173867A/en unknown
- 2009-02-26 WO PCT/US2009/035276 patent/WO2009108775A2/en active Application Filing
- 2009-02-26 AU AU2009219292A patent/AU2009219292B2/en active Active
- 2009-02-26 CN CN201310484741.7A patent/CN103751091B/zh active Active
- 2009-02-26 BR BRPI0908539A patent/BRPI0908539B8/pt active IP Right Grant
- 2009-02-26 JP JP2010548864A patent/JP5547096B2/ja active Active
- 2009-02-26 CN CN2009801157337A patent/CN102036655B/zh active Active
- 2009-02-26 EP EP09713721.0A patent/EP2247284B1/en active Active
- 2009-02-26 US US12/393,584 patent/US20090226522A1/en not_active Abandoned
- 2009-02-26 ES ES09713721.0T patent/ES2633928T3/es active Active
- 2009-02-26 CA CA2716901A patent/CA2716901C/en active Active
- 2009-02-26 RU RU2010139643/15A patent/RU2010139643A/ru not_active Application Discontinuation
- 2009-02-26 DK DK09713721.0T patent/DK2247284T3/en active
- 2009-02-27 AR ARP090100677A patent/AR072245A1/es not_active Application Discontinuation
-
2010
- 2010-08-26 IL IL207824A patent/IL207824A/en active IP Right Grant
- 2010-09-07 ZA ZA2010/06421A patent/ZA201006421B/en unknown
-
2011
- 2011-08-19 HK HK11108783.1A patent/HK1154505A1/xx unknown
-
2013
- 2013-12-11 JP JP2013256105A patent/JP2014062119A/ja active Pending
-
2017
- 2017-06-06 IL IL252713A patent/IL252713A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0908539B8 (pt) | 2021-05-25 |
US20090226522A1 (en) | 2009-09-10 |
EP2247284A4 (en) | 2013-10-02 |
WO2009108775A3 (en) | 2009-12-03 |
ZA201006421B (en) | 2011-05-25 |
AR072245A1 (es) | 2010-08-18 |
CN102036655B (zh) | 2013-11-20 |
HK1154505A1 (en) | 2012-04-27 |
RU2010139643A (ru) | 2012-04-10 |
KR101473419B1 (ko) | 2014-12-16 |
CN103751091B (zh) | 2017-08-25 |
EP2247284A2 (en) | 2010-11-10 |
CN103751091A (zh) | 2014-04-30 |
AU2009219292B2 (en) | 2014-02-27 |
IL207824A0 (en) | 2010-12-30 |
EP2247284B1 (en) | 2017-04-19 |
BRPI0908539B1 (pt) | 2020-12-08 |
MY173867A (en) | 2020-02-25 |
JP2014062119A (ja) | 2014-04-10 |
CA2716901A1 (en) | 2009-09-03 |
NZ587611A (en) | 2012-07-27 |
AU2009219292A1 (en) | 2009-09-03 |
KR20100123740A (ko) | 2010-11-24 |
IL252713A0 (en) | 2017-08-31 |
ES2633928T3 (es) | 2017-09-26 |
MX2010009493A (es) | 2010-12-20 |
CA2716901C (en) | 2018-07-03 |
CN102036655A (zh) | 2011-04-27 |
WO2009108775A2 (en) | 2009-09-03 |
JP2011513324A (ja) | 2011-04-28 |
DK2247284T3 (en) | 2017-07-31 |
IL207824A (en) | 2017-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5547096B2 (ja) | 多型を最小化する方法 | |
JP4875001B2 (ja) | アリピプラゾールの湿式造粒医薬組成物 | |
JP4501054B2 (ja) | ナテグリニド含有製剤 | |
JP6150888B2 (ja) | リファキシミン及びアミノ酸を含む医薬組成物、その調製方法及びその使用 | |
JP2019214605A (ja) | ブルトンチロシンキナーゼの阻害剤を含む剤形組成物 | |
JP2012512840A (ja) | ラサギリン成分を含有する固体組成物 | |
JPH08208480A (ja) | 改良された溶解速度を持つネファゾドンの塩 | |
TW202112376A (zh) | 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法 | |
EP2165702B1 (en) | Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation | |
CN104853752B (zh) | 嘧啶二酮衍生物化合物的制剂 | |
JPWO2016175230A1 (ja) | 経口投与用医薬組成物 | |
WO2020225738A1 (en) | Pharmaceutical composition comprising venetoclax | |
JP3470096B2 (ja) | ニルバジピン含有易溶性固形製剤およびその製造法 | |
WO2022034914A1 (ja) | 易溶性固形製剤およびその製法 | |
KR20070103709A (ko) | 고체 분산체의 필름 코팅방법 | |
WO2024095296A1 (en) | Solvent free solid oral composition of bcs class iv drugs | |
JP2003146878A (ja) | ニルバジピン含有易溶性固形製剤およびその製造法 | |
JP2023506920A (ja) | ポリマーマトリックス中に分散されたピラゾール化合物の医薬組成物 | |
JPWO2015199115A1 (ja) | 経口投与用医薬組成物 | |
EP3079672A1 (en) | Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline | |
LUST | ANDRES LUST | |
Kavitha | Enhancement of Solubility of Repaglinide Through Solid Dispersion Methods | |
Arther Paul | Formulation And Evaluation of Orodispersible Tablets of Domperidone from Selected Solid Dispersions–An Attempt to Improve in Vitro Dissolution, Patient Compliance and Marketability | |
JPH04169585A (ja) | (S)―10―(1―アミノシクロプロピル)―9―フルオロ―3―メチル―7―オキソ―2,3―ジヒドロ―7H―ピリド[1,2,3―de][1,4]ベンゾオキサジン―6―カルボン酸の製剤化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110912 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130523 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130911 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131211 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140414 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140514 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5547096 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |